Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CD19+ Chimeric Antigen Receptor T Cells for Patients With Advanced Lymphoid Malignancies

NCT02529813 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT02529813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02529813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CD19+ Chimeric Antigen Receptor T Cells for Patients With Advanced Lymphoid Malignancies
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Completed
Start date
December 16, 2015
Completion date
November 8, 2021
Enrollment
26 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute biphenotypic leukemia, acute lymphoblastic leukemia, blasts 5 percent or more of bone marrow nucleated cells, cd19 positive, minimal residual disease, non-hodgkin lymphoma, small lymphocytic lymphoma, stage iii chronic lymphocytic leukemia, stage iv chronic lymphocytic leukemia